Esketamine, offers a breakthrough treatment option for individuals struggling with treatment-resistant depression. As an FDA-approved medication, Esketamine has demonstrated significant benefits in improving mood and alleviating depressive symptoms when used in conjunction with an oral antidepressant. By targeting the glutamate system in the brain, Esketamine helps restore synaptic connections, providing a unique mechanism of action compared to traditional antidepressants. This innovative treatment has shown promise in rapidly reducing depressive symptoms, offering hope to patients who have not responded to multiple standard antidepressant medications. Administered under the supervision of a healthcare professional, Esketamine provides a safe and effective option for individuals seeking relief from the burdens of treatment-resistant depression.”